Barclays Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $203
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT) but lowers the price target from $226 to $203.

August 08, 2024 | 12:25 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays analyst Gena Wang maintains an Overweight rating on Sarepta Therapeutics but lowers the price target from $226 to $203.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some concerns or adjustments in expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100